Eagle Asset Management Inc. Has $11.12 Million Holdings in Glaukos Co. (NYSE:GKOS)

Eagle Asset Management Inc. cut its position in Glaukos Co. (NYSE:GKOS - Free Report) by 12.3% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 78,455 shares of the medical instruments supplier's stock after selling 10,978 shares during the quarter. Eagle Asset Management Inc. owned approximately 0.14% of Glaukos worth $11,121,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of GKOS. EFG Asset Management North America Corp. lifted its stake in shares of Glaukos by 0.5% in the 2nd quarter. EFG Asset Management North America Corp. now owns 27,205 shares of the medical instruments supplier's stock valued at $3,216,000 after purchasing an additional 128 shares in the last quarter. Values First Advisors Inc. bought a new position in shares of Glaukos during the third quarter worth about $25,000. New York State Teachers Retirement System grew its position in shares of Glaukos by 0.4% in the 3rd quarter. New York State Teachers Retirement System now owns 48,143 shares of the medical instruments supplier's stock worth $6,272,000 after acquiring an additional 200 shares in the last quarter. KBC Group NV lifted its position in shares of Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier's stock worth $188,000 after buying an additional 201 shares during the last quarter. Finally, Inspire Investing LLC boosted its stake in Glaukos by 6.9% in the third quarter. Inspire Investing LLC now owns 3,193 shares of the medical instruments supplier's stock valued at $416,000 after acquiring an additional 206 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GKOS has been the topic of a number of recent analyst reports. Truist Financial lifted their price target on Glaukos from $145.00 to $152.00 and gave the company a "buy" rating in a report on Monday, October 14th. StockNews.com upgraded shares of Glaukos from a "sell" rating to a "hold" rating in a report on Monday, October 21st. Wells Fargo & Company upped their price target on Glaukos from $135.00 to $145.00 and gave the company an "overweight" rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. lifted their target price on Glaukos from $130.00 to $145.00 and gave the stock an "overweight" rating in a report on Tuesday, November 5th. Finally, BTIG Research lifted their price target on Glaukos from $131.00 to $139.00 and gave the stock a "buy" rating in a research note on Wednesday, August 28th. Four research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Glaukos has a consensus rating of "Moderate Buy" and a consensus price target of $134.55.

Glaukos Stock Up 2.3 %

Shares of GKOS traded up $3.17 during mid-day trading on Friday, hitting $144.00. 549,002 shares of the company's stock were exchanged, compared to its average volume of 593,848. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. Glaukos Co. has a twelve month low of $59.22 and a twelve month high of $146.09. The firm has a fifty day moving average of $132.40 and a two-hundred day moving average of $123.58. The stock has a market cap of $7.94 billion, a price-to-earnings ratio of -47.68 and a beta of 1.02.

Glaukos (NYSE:GKOS - Get Free Report) last posted its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million for the quarter, compared to analyst estimates of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business's revenue was up 23.9% compared to the same quarter last year. During the same period last year, the company earned ($0.50) earnings per share. On average, sell-side analysts forecast that Glaukos Co. will post -1.96 earnings per share for the current year.

Insider Activity

In other news, Director Gilbert H. Kliman sold 3,000 shares of the company's stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the sale, the director now directly owns 32,336 shares in the company, valued at approximately $4,225,345.12. This represents a 8.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO Joseph E. Gilliam sold 2,275 shares of the business's stock in a transaction on Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the sale, the chief operating officer now owns 102,169 shares in the company, valued at $14,198,425.93. This represents a 2.18 % decrease in their position. The disclosure for this sale can be found here. Insiders own 6.40% of the company's stock.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.